SCHEMBL26928697

SCHEMBL26928697

Clc1ccc(Nc2nccc3occc23)cn1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FADS1 O60427 1/20 0.60
DRD1 P21728 2/20 0.45
GRM4 Q14833 1/20 0.43
TNF P01375 2/20 0.42
PIK3CA P42336 1/20 0.40
KCNQ3 O43525 4/20 0.39
KCNQ2 O43526 4/20 0.39
KCNQ1 P51787 3/20 0.39
TRPA1 O75762 2/20 0.39
SCN5A Q14524 1/20 0.39
CHRNA7 P36544 1/20 0.37
HTR3A P46098 1/20 0.37
KCNE1 P15382 2/20 0.33
HTR2C P28335 1/20 0.33
BACE1 P56817 1/20 0.33
NOTUM Q6P988 1/20 0.33
AURKA O14965 1/20 0.32
MKNK1 Q9BUB5 1/20 0.32
PIN1 Q13526 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30738032 1.00 FADS1 (0.60) FADS1DRD1GRM4TNFPIK3CA
Formic Acid SCHEMBL26928810 0.92 FADS1 (0.53) FADS1DRD1GRM4TNFPIK3CA
Formic Acid SCHEMBL30738123 0.92 FADS1 (0.53) FADS1DRD1GRM4TNFPIK3CA
SCHEMBL30737893 0.77 ASIC3 (0.51) FADS1GRM4TNFPIK3CAKCNQ3
SCHEMBL26928464 0.77 ASIC3 (0.51) FADS1GRM4TNFPIK3CAKCNQ3
SCHEMBL4742014 0.75 FADS1 (1.00) FADS1DRD1TNFHTR3AMKNK1
SCHEMBL26928701 0.75 GRM4 (0.47) GRM4TNFPIK3CAKCNQ3KCNQ2
SCHEMBL30737928 0.72 GRM4 (0.42) FADS1GRM4TNFPIK3CAKCNQ3
SCHEMBL30824385 0.72 TNF (0.51) FADS1GRM4TNFPIK3CAKCNQ3
SCHEMBL26928553 0.72 GRM4 (0.42) FADS1GRM4TNFPIK3CAKCNQ3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240101531-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS XENON PHARMACEUTICALS INC. (CA) 2024-03-28 US claimed
WO-2023239729-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS XENON PHARMACEUTICALS INC. (CA) 2023-12-14 WO claimed
US-20240101531-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS XENON PHARMACEUTICALS INC. (CA) 2024-03-28 US disclosed
WO-2023239729-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS XENON PHARMACEUTICALS INC. (CA) 2023-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101531-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS KCNA1, KCNB1, KCNB2 FADS1 1513/4885DRD1 977/4885GRM4 320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.